After a rough regulatory start to the year, India’s Aurobindo Pharma is charting plans for growth. The Hyderabad-based generics juggernaut will plow 3 billion Indian rupees (about $37.7 million) into ...

Pharmaceutical major Aurobindo Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Unit III in the Bachupally Village, Telangana . The ...

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has entered into a marketing and distribution agreement ...

Aurobindo Pharma has repeatedly defended its key moving average supports, as it refused to trade below the 50-day and 20-day ...

Bad news for Aurobindo Pharma. Just two months after the generics maker closed up shop at its Aurolife Pharma unit in New Jersey, the company’s oral manufacturing facility in Hyderabad, India, was ...

Aurobindo Pharma Share Price hits 52-week high of ₹1,321 on USFDA VAI classification, Pen-G import policy; JM Financial ...

Hyderabad: Aurobindo Pharma Limited has deferred the completion timeline for its planned investment in Swarnaakshu Solar ...

Teva and Auspex Pharmaceuticals, U.S. affiliates of Teva Pharmaceutical, have reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s ANDA for a generic deutetrabenazine product.

Patients with pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate have a new generic treatment option available. The Food and Drug ...

The revenue increased by approximately 9.39 percent in 2025 compared to 2024. Similarly, the net profit saw an increase of around 10.34 percent during the same period. The total assets of Aurobindo ...

Hyderabad-headquartered drugmaker, Aurobindo Pharma earned a consolidated net profit of ₹505.9 crore in Q4 of FY23, declining by 12.2% from a profit of ₹576.1 crore a year ago same quarter. Aurobindo ...